Key Presentations on Advanced Non–Small Cell Lung Cancer From ASCO 2021

Dr Mark A. Socinski, executive medical director of AdventHealth Cancer Institute in Orlando, Florida, highlights studies in advanced non–small cell lung cancer (NSCLC) presented at the 2021 annual meeting of the American Society of Clinical Oncology.
First, Dr Socinski reports on the updated results of the CheckMate 9LA study showing continued benefit of nivolumab and ipilimumab plus chemotherapy vs chemotherapy alone.

He also outlines an FDA pooled analysis of randomized controlled trials showing that patients with PD-L1 scores between 1% and 49% benefit most from immunotherapy plus chemotherapy compared with immunotherapy alone.

Dr Socinski then takes us through one of his own studies showing that immune-related adverse events are actually associated with better outcomes, and reports some sobering data from two studies suggesting that biomarker testing is lagging behind in NSCLC patients, especially among African Americans. He closes by reviewing updated results of the CodeBreak 100 trial which showed encouraging response to sotorasib among patients with G12C KRAS mutations.

--

Mark A. Socinski, MD, Executive Medical Director, AdventHealth Cancer Institute, Orlando, Florida.

Mark A. Socinski, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Genentech; Novartis; Guardant; AstraZeneca; Eli Lilly and Company; Blueprint
Received research grant from: Genentech; AstraZeneca; Novartis; Spectrum; Cullinan.

Dr Mark A. Socinski, executive medical director of AdventHealth Cancer Institute in Orlando, Florida, highlights studies in advanced non–small cell lung cancer (NSCLC) presented at the 2021 annual meeting of the American Society of Clinical Oncology.
First, Dr Socinski reports on the updated results of the CheckMate 9LA study showing continued benefit of nivolumab and ipilimumab plus chemotherapy vs chemotherapy alone.

He also outlines an FDA pooled analysis of randomized controlled trials showing that patients with PD-L1 scores between 1% and 49% benefit most from immunotherapy plus chemotherapy compared with immunotherapy alone.

Dr Socinski then takes us through one of his own studies showing that immune-related adverse events are actually associated with better outcomes, and reports some sobering data from two studies suggesting that biomarker testing is lagging behind in NSCLC patients, especially among African Americans. He closes by reviewing updated results of the CodeBreak 100 trial which showed encouraging response to sotorasib among patients with G12C KRAS mutations.

--

Mark A. Socinski, MD, Executive Medical Director, AdventHealth Cancer Institute, Orlando, Florida.

Mark A. Socinski, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Genentech; Novartis; Guardant; AstraZeneca; Eli Lilly and Company; Blueprint
Received research grant from: Genentech; AstraZeneca; Novartis; Spectrum; Cullinan.

Dr Mark A. Socinski, executive medical director of AdventHealth Cancer Institute in Orlando, Florida, highlights studies in advanced non–small cell lung cancer (NSCLC) presented at the 2021 annual meeting of the American Society of Clinical Oncology.
First, Dr Socinski reports on the updated results of the CheckMate 9LA study showing continued benefit of nivolumab and ipilimumab plus chemotherapy vs chemotherapy alone.

He also outlines an FDA pooled analysis of randomized controlled trials showing that patients with PD-L1 scores between 1% and 49% benefit most from immunotherapy plus chemotherapy compared with immunotherapy alone.

Dr Socinski then takes us through one of his own studies showing that immune-related adverse events are actually associated with better outcomes, and reports some sobering data from two studies suggesting that biomarker testing is lagging behind in NSCLC patients, especially among African Americans. He closes by reviewing updated results of the CodeBreak 100 trial which showed encouraging response to sotorasib among patients with G12C KRAS mutations.

--

Mark A. Socinski, MD, Executive Medical Director, AdventHealth Cancer Institute, Orlando, Florida.

Mark A. Socinski, MD, has disclosed the following relevant financial relationships:
Serve(d) as a speaker or a member of a speakers bureau for: Genentech; Novartis; Guardant; AstraZeneca; Eli Lilly and Company; Blueprint
Received research grant from: Genentech; AstraZeneca; Novartis; Spectrum; Cullinan.